Fundraising Fox
Tectonic Therapeutic
Watertown, US · Founded 2019 · 69 employees on LinkedIn · 12 known investors
Find your way into Tectonic Therapeutic
Sign up to see every warm intro you have to Tectonic Therapeutic
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Tectonic Therapeutic team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™. The company focuses on therapeutic areas with significant unmet medical needs where current treatment options are limited or absent.
Founders & leadership
Tectonic Therapeutic was founded in 2019 by Timothy A. Springer and Andrew C. Kruse.
TA
Timothy A. SpringerCo-Founder
AC
Andrew C. KruseCo-founder
AR
Alise ReicinCEO and PresidentAlise Reicin is a physician with two decades of drug development experience across oncology, hematology, autoimmune, and allergic diseases; she has contributed to bringing over 10 drugs to market and led clinical development efforts for Keytruda across multiple tumor types.
DL
Daniel LochnerExecutive
MK
Marcella K. RuddyExecutive
CC
Christian CortisStrategic Advisor2024–2025Christian Cortis is a biotechnology executive with experience in venture capital investment and senior roles at private and public companies. He has served as an independent director at OpenEye Scientific Software, which was acquired by Cadence Systems for $500 million in 2022.
GM
Geoffrey MacKayExecutive
CM
Christopher MasonExecutive
KW
Kim WarrenExecutive
DP
Deanna PetersenExecutive
Investors · 12
Vida Ventureslisted by Vida VenturesLos Angeles
How we know: Vida Ventures's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Polaris PartnersreportedBoston · $500K – $5Mvia Terry McGuire · board
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Soleus CapitalreportedGreenwich
How we know: stocktitan.net · Not right? Tell us
Also in the syndicate · 6
Adage Capital Partners LPDeep Track CapitalFarallon Capital Management, L.L.C.StemPoint Capital LPTAS PartnersWoodline Partners LP
Reported raises · per SEC filings
Form D private placements$333.1M disclosed across 4 rounds · 2016–2025
▶$185MraisedFeb 2025 · 29 investors · BiotechnologyRule 506(b)
▶$185MraisedFeb 2025 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alise ReicinExecutive Officer, Director
- Phillip B. DonenbergDirector
- Timothy SpringerDirector
- Daniel LochnerExecutive Officer
- Terrance McGuireDirector
- Marc SchwabishExecutive Officer
- Peter McNamaraExecutive Officer
- Marcella K. RuddyExecutive Officer
- Praveen P. TipirneniDirector
- Stefan VitorovicDirector
- Offering amount
- $185M
- Amount sold
- $185M
- Sales commissions
- $11.1M
- Placement agents
- Piper Sandler & Co., Leerink Partners LLC, TD Securities (USA) LLC, Wells Fargo Securities, LLC
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$80.1MraisedApr 2021 · 23 investors · BiotechnologyRule 506(b)
▶$80.1MraisedApr 2021 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew KruseDirector
- Timothy A. SpringerDirector
- Terry McGuireDirector
- Christian CortisExecutive Officer
- Stefan VitorovicDirector
- Praveen TipirneniDirector
- Alise ReicinExecutive Officer, Director
- Offering amount
- $80.1M
- Amount sold
- $80.1M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$60.5MraisedFeb 2018 · 15 investors · BiotechnologyRule 506(b)
▶$60.5MraisedFeb 2018 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Geoffrey MacKayExecutive Officer, Director
- Christopher MasonExecutive Officer
- Scott RequadtDirector
- Kim WarrenExecutive Officer
- Deanna PetersenExecutive Officer
- Joshua ResnickDirector
- Christopher PaigeDirector
- Katina DortonExecutive Officer
- Ian ClarkDirector
- Bruce BoothDirector
- Offering amount
- $61M
- Amount sold
- $60.5M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$7.5MraisedAug 2016 · 3 investors · BiotechnologyRule 506(b)
▶$7.5MraisedAug 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Geoffrey MacKayExecutive Officer, Director
- Christopher MasonExecutive Officer
- Kim WarrenExecutive Officer
- Joshua ResnickDirector
- Deanna PetersenExecutive Officer
- Bruce BoothDirector
- Scott RequadtDirector
- Christopher PaigeDirector
- Offering amount
- $25M
- Amount sold
- $7.5M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Context TherapeuticsContext Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors. Its pipeline targets antigens such as Claudin 6, mesothelin, and Nectin-4 to direct the immune system against difficult-to-treat cancers.
Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Companies working in the same space as Tectonic Therapeutic.
Frequently asked questions
- What does Tectonic Therapeutic do?
- Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™. The company focuses on therapeutic areas with significant unmet medical needs where current treatment options are limited or absent.
- Who founded Tectonic Therapeutic?
- Tectonic Therapeutic was founded by Timothy A. Springer, Andrew C. Kruse in 2019.
- Who are Tectonic Therapeutic's investors?
- Tectonic Therapeutic's investors include EcoR1 Capital, Vida Ventures, Ally Bridge Group, Clarus Ventures, Polaris Partners, Soleus Capital.
- How much funding has Tectonic Therapeutic raised?
- Tectonic Therapeutic has disclosed $333.1M raised across 4 rounds.
- Where is Tectonic Therapeutic headquartered?
- Tectonic Therapeutic is headquartered in Watertown, US.